Daily Stock List
Heritage Global, Inc. (HGBL)
SmallCapVoice reported recently on Heritage Global, Inc. (HGBL), TheMicrocapNews did previously, and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.
Heritage Global, Inc. is a leader in asset liquidation transactions, valuations, and advisory services. The Company centers on identifying, valuing, acquiring, as well as monetizing underlying assets in 28 global manufacturing and technology sectors. Its operating companies are Heritage Equity Partners, Heritage Global Partners, Heritage Global Valuations, Heritage NLEX, and Heritage Zetabid Realty Services. Heritage Global has its headquarters in San Diego, California.
Its goal going forward is to conduct all of its business under its two primary platforms: Heritage Global Partners for auctions, valuations, acquisitions and dispositions of surplus assets and plant closures, and Heritage Equity Partners (HEP) for advisory services and disposition services of distressed and non-distressed ongoing enterprise sales. Heritage Equity Partners (HEP), formerly “Equity Partners,” is headquartered in Easton, MD. HEP provides boutique investment banking services for special situations.
Heritage Global specializes in acting as an adviser and acquiring or brokering turnkey manufacturing facilities, surplus industrial machinery and equipment, industrial inventories, accounts receivable portfolios and related intellectual property (IP), and entire business enterprises. It has completed hundreds of transactions since forming, acting as principal and advisor and member of various syndicates together with distressed and surplus asset industry leaders.
Heritage Global has launched the aforementioned Heritage Zetabid Realty Services (HZRS). This is its newly formed real estate auction platform and services division. HZRS complements and expands Heritage Global’s existing asset valuation, advisory, and auction capabilities through adding new service offerings and experienced industry professionals to effectively market and monetize clients’ commercial, industrial, and luxury/bank-owned residential real estate assets. Heritage Zetabid Realty Services is a strategic alliance between Heritage Global and Zetabid, a foremost provider of real estate marketing services.
Heritage Global has also launched Heritage Global Capital (HGC). This is its newly formed fixed asset financing services division. HGC complements and expands Heritage Global’s existing asset valuation, advisory, and auction capabilities by adding new service offerings focused on providing term loans and leases secured by equipment and real estate.
Heritage Global Partners (HGP) will manage an upcoming worldwide online auction from four locations featuring surplus metal working and machine shop assets of Compressor Products International (CPI). CPI is a division of EnPro Industries. The worldwide online auction will begin on December 15, 2015. CPI is a ground-breaking global manufacturing and services business. It offers precision engineered compressor components, lubrication systems and support services to compressor operators.
Heritage Global, Inc. (HGBL), closed Tuesday's trading session at $0.2465, up 17.38%, on 800 volume with 2 trades. The average volume for the last 60 days is 11,754 and the stock's 52-week low/high is $0.05/$0.51.
Event Cardio Group, Inc. (ECGI)
TopPennyStockMovers, SmallCapVoice, StockHotTips, and PennyTrader reported earlier on Event Cardio Group, Inc. (ECGI), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Event Cardio Group, Inc. is a medical device company listed on the OTCQB. The Company is a developer of medical diagnostic detection equipment that centers on the detection and preventive treatment of high-risk diseases. Event Cardio’s dedication is to providing life-enhancing, inventive medical products to the public by way of partnerships with non-profit organizations, corporations, academia, the government, and individuals. Event Cardio Group is based in New York, New York.
The Company operates in the cardiac medical device innovation, patient monitoring, as well as cardiac event prediction industry. Its core products include its’ NowCardio™. This is an advanced cardiac monitor, which offers dual-functionality including holter monitoring and event recording simultaneously. NowCardio™ is an inventive medical device designed by CONTEX International Technologies (Canada), Inc., a healthcare and aerospace high technology engineering company.
Event Cardio’s core products also include the Food and Drug Administration (FDA) approved BreastCare DTS™ breast cancer detection device. BreastCare DTS™ is a user-friendly, single-use device. BreastCare DTS™ has received FDA 510K clearance for marketing in the United States.
BreastCare DTS™ is a non-invasive device. It enables women to safely and affordably screen for breast cancer throughout the year, in combination with annual or bi-annual mammography and clinical breast examination.
The patented device consists of two soft, disposable pads that are lightweight and non-invasive. They are 98 percent accurate as an early detector of possible breast cancer. The BreastCare DTS™ device is not intended to replace mammography, ultrasound and other detection methods. It is to be used as an adjunct to these screening methods.
This past September, Event Cardio Group announced the appointment of Ms. Julie Singleton as Chief Executive Officer (CEO) of its BreastCare Division and to its Board of Directors. Ms. Singleton presently serves as CEO at MedPac Asia Pacific PTY Ltd, of Australia, exclusive South East Asia Distributor of Event Cardio Group's BreastCare DTS ® and NowCardio.
Event Cardio Group, Inc. (ECGI), closed Tuesday's trading session at $0.04, up 33.33%, on 393,850 volume with 10 trades. The average volume for the last 60 days is 51,384 and the stock's 52-week low/high is $0.0282/$0.25.
Novus Robotics, Inc. (NRBT)
Wallstreetlivechat, OTC Stock Review, and Market Bulls reported previously on Novus Robotics, Inc. (NRBT), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
Novus Robotics, Inc. engages in the engineering, design, and manufacture of robotics and automation technology solutions for tube bending machines. The Company’s wholly-owned subsidiary is D & R Technology, Inc. Through D & R Technology, Novus Robotics will provide state of the art automation technologies by way of its automated tube bending machines. It designs, engineers, and builds these for the automotive industry to solve its customers' complex automation needs, increase efficiencies, and improve manufacturing processes. Novus Robotics is based in Mississauga, Ontario.
Novus Robotics’ automated solutions can be found in manufacturing, assembly and processing lines throughout the U.S., Canada, Mexico, and South America. The Company will provide automation solutions to a broad assortment of customers and industries. These range from large Fortune 500 companies to small privately-held businesses. Novus Robotics is a full service provider of turn-key production solutions. It specializes in tubular components for its tube bending machines.
The Company’s principal activities to date include designing and the installation of retrofits to existing automated systems, automated spare parts for its tube bending machines, automated maintenance, and repairs. At present, it is offering products including Seat Frame Systems, IP Tube systems, and Integrated Bend-Weld Systems for the automotive industry.
Novus’ D & R Technology subsidiary also makes custom-built tooling, provides process development, production support, continuing service, preventive maintenance and more. D & R Technology is emerging as one of the world’s top providers of automated manufacturing solutions, used by three of the top ten automotive part suppliers globally. D&R Technology is applying its service solutions to other markets. These include medical robotics, personal robotic devices, and also the water treatment industry.
Novus Robotics has developed partnerships with market leaders. Through these developed partnerships it provides its customers with business consulting; implementation services; integration solutions; design collaboration; and complementary products essential for successful deployment of its solutions. Its chief emphasis is on product engineering and manufacturing processes to ensure the highest quality, product features, and efficient manufacturing processing.
The Company’s expertise is in the areas of automation and machinery for computer numerical control (CNC) bending, forming, piercing, and laser cutting. It produces spare parts for the manufacturing equipment it designs. However, Novus Robotics does not produce spare parts for automobiles.
Novus Robotics, Inc. (NRBT), closed Tuesday's trading session at $0.028, up 24.44%, on 83,500 volume with 7 trades. The average volume for the last 60 days is 44,720 and the stock's 52-week low/high is $0.0149/$0.14.
PeerLogix, Inc. (LOGX)
MoneyTV, PennyPickAlerts, Fortune Stock Alerts, Stock Commander, Fast Money Alerts, Stock Shock and Awe, Penny Stock General, and Shiznit Stocks reported recently on PeerLogix, Inc. (LOGX), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Established in 2014, PeerLogix, Inc. is an advertising technology and data aggregation provider. The Company provides a proprietary software as a service (SAAS) platform that allows the tracking and cataloguing of Torrent files and Torrent networks to determine consumer trends and preferences based upon media consumption. PeerLogix has its corporate headquarters in New York, New York. The Company’s shares trade on the OTC Bulletin Board.
PeerLogix’ geography agnostic platform is used by roughly 130 million people around the world to share TV shows, movies, music, pictures, video games, e-books, and software with one another. By way of its proprietary technology, the Company tracks almost every global Torrent transaction.
Its patent pending platform collects Torrent data, including IP addresses of the uploading and downloading parties, the name, file type, media type, and genre of media downloaded, and uses licensed and publicly available demographic and other databases to further filter the collected data to provide insights into consumer preferences to digital advertising firms, product and media companies, entertainment studios and others.
Last month, PeerLogix announced the results of a targeted advertising campaign to grow ticket sales executed on behalf of Republic Live, presenters of the WayHome Music and Arts Festival. This was the first annual WayHome festival, a co-production between Republic Live and AC Entertainment. Through using its wide-ranging data, analytics and industry leading software, PeerLogix delivered an 81 percent improvement in advertising performance with its Torrent remarketing group than those of an independent Control group.
Last week, PeerLogix announced the top ten Tim Burton film downloads on torrent. The Nightmare Before Christmas (1993) is the leading Torrent download by a broad margin. Furthermore, an analysis of the specific times of the year when the film is downloaded confirms its high degree of popularity during the Halloween and Christmas seasons. On the whole, Tim Burton films made in the last 15 years have had the greatest impact on the Torrent community.
PeerLogix, Inc. (LOGX), closed Tuesday's trading session at $0.42, up 40.00%, on 54,756 volume with 25 trades. The average volume for the last 60 days is 9,173 and the stock's 52-week low/high is $0.25/$2.50.
Cerebain Biotech Corp. (CBBT)
Greenbackers reported previously on Cerebain Biotech Corp. (CBBT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
A development-stage medical device company, Cerebain Biotech Corp. focuses on the creation and clinical development of a minimally invasive implantable device and a synthetic drug solution. The Company previously went by the name Discount Dental Materials, Inc. It changed its name to Cerebain Biotech Corp. in June of 2014. The Company has its corporate head office in Dallas, Texas.
Cerebain Biotech’s device takes advantage of the clinically observable, positive impact that omentum stimulation has on cognitive function as related to dementias, and in particular, Alzheimer’s disease. The Company’s patent-pending device is implanted in the omentum, which is a protective layer of skin that protects the abdominal organs.
The design of the device is to stimulate the omentum in patients with Alzheimer’s Disease. Omental stimulation has been shown to improve cognitive function in patients with dementias. This includes Alzheimer’s Disease.
Regarding Cerebain’s technology, it has allowed for the development of a medical device that can be implanted using a minimally invasive procedure. Upon implantation, through what will probably be a same-day surgery procedure, patients may not have to undergo surgery again using this treatment method. Cerebain Biotech has a manufacturing agreement with Sonos Medical, a medical device supplier.
Cerebain said recently that its research suggests it has three options for implantable devices with a predisposition towards having them as non-invasive as possible. The options consist of two electro-stim types, which have a multitude of variable test parameters that can be changed and modified externally as the testing facility conducts clinical trials on each patient. Cerebain said that manufacturing should commence in 2016.
In the coming months, Cerebain Biotech’s plan is to strategically prepare for the start of its clinical trial studies in Q1 or Q2 2016. This includes necessary filings and strategic partnerships. In addition, the Company plans to allocate resources to administer grant applications for further research and testing of its existing technology.
It also plans to design a surgical manual to be used by doctors and clinicians for the purpose of implanting its medical device. Furthermore, its plan includes providing additional administrative and financial support to its scientists to take advantage of their time to advance the Company’s technologies in or near trials.
Cerebain Biotech Corp. (CBBT), closed Tuesday's trading session at $0.31, up 28.05%, on 3,075 volume with 2 trades. The average volume for the last 60 days is 6,546 and the stock's 52-week low/high is $0.18/$1.49.
Freedom Leaf Inc. (FRLF)
The QualityStocks Daily Newsletter would like to spotlight Freedom Leaf Inc. (FRLF). Today, Freedom Leaf Inc. closed trading at $0.34, even for the day. The stock’s average daily volume over the past 60 days is 387, and its 52-week low/high is $0.05/$1.00.
Freedom Leaf Inc. announced today that it is launching a local licensing and publishing effort to boost its presence on the grass roots level. The company's new program offers revenue-generating opportunities for State Ambassador Licensees to sell city licenses to prospects, coordinate with City Directors and work on growth prospects by leveraging the Freedom Leaf brand. With the backing of the Freedom Leaf banner, a network of Local Ambassadors will establish themselves as the local experts in the emerging medical marijuana, cannabis and industrial hemp industries.
Freedom Leaf Inc. (FRLF), The Marijuana Legalization Company™, is a leading marijuana-related news, multi-media, entertainment, branding, business development, and incubation company with an ever-expanding online presence.
As a staunch national advocate of various state initiatives to legalize medical and recreational marijuana, Freedom Leaf has an entire platform of online content suited for every aspect of advertising and marketing for all businesses in the cannabis industry. These websites incorporate many aspects of the marijuana industry and movement. Freedom Leaf's current websites include:
• Cannabis Business University
Freedom Leaf founders have been involved in marijuana legalization for more than 45 years, delivering to the corporation keen industry insight and guidance on expansion initiatives. Freedom Leaf does not handle, grow, sell or dispense marijuana or related products, and therefore is not regulated in any way by the different government agencies other than standard business type of regulations. Disclaimer
Freedom Leaf Inc. Company Blog
Freedom Leaf Inc. News:
Freedom Leaf Licensing Its Brand for National Growth on the Grass Roots Level
Freedom Leaf, Inc. Named as Brand Ambassador of NORML
Freedom Leaf, Inc. (FRLF) Announces Engagement of QualityStocks Investor Relations Services
Cherubim Interests, Inc. (CHIT)
The QualityStocks Daily Newsletter would like to spotlight Cherubim Interests, Inc. (CHIT). Today, Cherubim Interests, Inc. closed trading at $0.0003, on 41,451,023 volume with 25 trades. The stock’s average daily volume over the past 60 days is 29,857,540, and its 52-week low/high is $0.0002/$0.33.
Cherubim Interests, Inc. was pleased to announce today its inaugural convertible preferred stock dividend for the shareholders of record as of December 31st, 2015. "One of the critical ingredients to being successful when building equity is to be able to quickly adjust where needed to take advantage of markets conditions and opportunities," says Patrick J. Johnson, CEO of Cherubim Interests. "This is why we're issuing the Convertible Securities - it's us seeing a need and moving swiftly to fill it."
Cherubim Interests, Inc. (CHIT) is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company's management team of experts in property management, construction and finance.
The company's primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.
Coupled with a real estate development and property management business model, BudCube Cultivation Systems ("BCS") can position itself anywhere in the world where the cultivation of cannabis is legal. BCS's unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.
Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product. Disclaimer
Cherubim Interests, Inc. Company Blog
Cherubim Interests, Inc. News:
Cherubim Interests, Inc. Announces End of Year Convertible Preferred Stock Dividend
Cherubim Interests (CHIT) Signs MOU With United Cannabis Corp. (CNAB)
Cherubim Interests, Inc. Goes Long with its Shareholders
Nutra Pharma Corp. (NPHC)
The QualityStocks Daily Newsletter would like to spotlight Nutra Pharma Corp. (NPHC). Today, On the Move Systems, Inc. closed trading at $0.111, up 40.51%, on 2,533,637 volume with 188 trades. The stock’s average daily volume over the past 60 days is 109,080, and its 52-week low/high is $0.0025/$0.27.
Nutra Pharma Corp. (NPHC) is a biotech company working in collaboration with its subsidiaries to develop an innovative pipeline of biopharmaceutical products for the management of neurological disorders, cancer, autoimmune, and infectious diseases. At the core of Nutra Pharma's intellectual property is a unique platform for extracting neurotoxins from Asian cobra venom and transforming them into non-toxic therapeutics.
The ReceptoPharm subsidiary, Nutra Pharm's drug discovery arm, is focused on the development of new therapeutic agents based upon specialized receptor-binding proteins found in nature, especially those found in snake venom from the cobra. ReceptoPharm's R&D pipeline consists of several novel therapies in various stages of development to prevent and/or treat multiple sclerosis (MS), human immunodeficiency virus (HIV), adrenomyeloneuropathy (AMN), herpes, rheumatoid arthritis (RA) and pain. The subsidiary also provides small and start-up biotech companies a full range of contract research services through its ISO class 5 and GMP certified facilities in Plantation, Florida.
Nutra Pharma recently received Orphan Drug Status from the FDA for the treatment of pediatric MS for its drug, RPI-78M. The designation of RPI-78M as an Orphan Drug provides Nutra Pharma with a seven-year period of market exclusivity in the U.S. once the drug is approved. Additional benefits over conventional drug applications include: tax credits for clinical research costs, the ability to apply for grant funding, clinical trial design assistance, plus assistance from the FDA in the drug development process and the waiver of Prescription Drug User Fee Act (PDUFA) filing fees which could be in excess of $2.5 million. The granting of Orphan Drug Designation allows Nutra Pharma to move forward with its preparation of an Investigative New Drug Application and proposal of clinical trials. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics.
ReceptoPharm holds all of the intellectual property for Nutra Pharma's drug pipeline, while Nutra Pharma directly holds all of the property dealing with their over-the-counter drugs. This includes Nyloxin, an OTC pain reliever for humans, and Pet Pain-Away, a pain reliever for dogs and cats. The company's Nyloxin product is the first OTC pain reliever clinically proven to treat moderate to severe chronic pain. The drug is available as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps and neuralgia and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
Nutra Pharma is a revenue-generating company with 12 patents and patents pending, three completed phase 1/phase 2 clinical trials, and 12 FDA-registered OTC products in the United States. The company also has regulatory clearance for Nyloxin in India, where management believes its initial distribution streams could become the company's biggest market. Management is also defining its plan to expand into China and Canada while strengthening its position the United States. Disclaimer
Nutra Pharma Corp. Company Blog
Nutra Pharma Corp. News:
StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corporation
Nutra Pharma's Rik Deitsch Interviewed by The Life Sciences Report
Nutra Pharma to Present at Upcoming Investment Conference
Oakridge Global Energy Solutions, Inc. (OGES)
The QualityStocks Daily Newsletter would like to spotlight Oakridge Global Energy Solutions, Inc. (OGES). Today, On the Move Systems, Inc. closed trading at $0.75, up 50.00%, on 1,400 volume with 5 trades. The stock’s average daily volume over the past 60 days is 21,153, and its 52-week low/high is $0.15/$2.40.
Oakridge Global Energy Solutions, Inc. (OGES) specializes in the development of cutting-edge technology to transform and synchronize freight supply chain operations for a broad range of industries. The company is exploring new online tools to reduce costs and increase convenience in the tourism and travel industry, as well as new opportunities in trucking. OMVS works with a premier group of international providers to offer its services in two key divisions: Trucking Logistics and Inter-modal Freight.
Logistics are critical to the success of any operation. OMVS's Trucking Logistics division operates as one of the most competitive, full-service transportation logistics providers in the United States. Utilizing the company's ISTx Platform, this division helps customers strategize how to get from one point to another, as well as solves some of the toughest logistics challenges on the road today. OMVS's Trucking Logistics technology provides customers increased visibility, minimal-cost route effectiveness, and delivery assurance.
OMVS's Intermodal Freight division offers seamless cargo continuation, tracking, shipping and receiving of goods anywhere in the world. The company's customer service teams and drivers communicate through the ISTx Platform allowing for flexibility, control and monitoring of each freight shipment. OMVS continues to research and explore the most effective and resourceful tools in order to effectively serve customers with unique shipping requirements in the billion dollar trucking industry.
In his more than 20 years of experience, OMVS president and CEO Robert Wilson has cultivated vast expertise as an executive and financial consultant for companies in aviation, energy, oil and gas, IT and healthcare. In addition to his work valuing and assessing small-to-middle market companies, Wilson has also served as both an officer and director of such client companies. Wilson applies his expertise in the transportation business and investment banking to spearhead OMVS's new initiative to create a new kind of online transportation platform to an international market. Disclaimer
Oakridge Global Energy Solutions, Inc. Company Blog
Oakridge Global Energy Solutions, Inc. News:
Oakridge Global Energy Solutions Announces Q3 Results
Oakridge Global Energy Solutions to Be Showcased In Upcoming “New To The Street” Series
Oakridge Announces Addition of Three Independent Board Members
Avant Diagnostics, Inc. (AVDX)
The QualityStocks Daily Newsletter would like to spotlight Avant Diagnostics, Inc. (AVDX). Today, Avant Diagnostics, Inc. closed trading at $0.36, up 38.46%, on 3,401 volume with 9 trades. The stock’s average daily volume over the past 60 days is 80,727, and its 52-week low/high is $0.001/$0.018.
Avant Diagnostics, Inc. (AVDX) is a medical diagnostic technology company that specializes in large panel biomarker screening. The company's first test, OvaDx®, is a sophisticated microarray-based test designed to detect pre-symptomatic ovarian cancer by measuring the activation of the immune system in blood samples in response to early stage ovarian tumor cell development.
In clinical development, OvaDx has indicated high sensitivity and specificity for all types and stages of ovarian cancer, including stage IA-IV borderline serous, clear cell, endometrioid, mixed epithelial, mucinous, serous and ovarian adenocarcinoma. Upon FDA approval, Avant plans to offer its diagnostic product as an elective test for women seeking greater wellness, as well as those in the elevated risk category for ovarian cancer.
OvaDx is also expected to be used by doctors to advance the forefront of ovarian cancer treatment, promoting the utilization of improved surgical options and more effective chemotherapies by serving as a supplement to existing tests, such as CA-125, OVA1® and transvaginal ultrasound. In this way, Avant's innovative product will promote earlier diagnoses and, as a result, improved survival rates for patients with ovarian cancer.
As it continues to seek FDA approval for its groundbreaking diagnostic technology, Avant is poised to promote considerable growth in the ovarian cancer market, addressing what is currently the most deadly cancer of the female reproductive system. The company will lean on the industry experience of its management team in order to continue positioning itself for long-term success in the medical diagnostic market. Disclaimer
Avant Diagnostics, Inc. Company Blog
Avant Diagnostics, Inc. News:
Avant Diagnostics Inc. Receives FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens
Avant Diagnostics Inc. Engages Goal Capital Inc. to Provide Investor Relations Services
Avant Diagnostics, Inc. Appoints Marcum LLP as Its New Independent Registered Public Accounting Firm
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Alternet Systems, Inc. (ALYI) CEO Featured in Exclusive QualityStocks Interview
- Avant Diagnostics, Inc. (AVDX) Receives FDA IRB Approval for OvaDx(R) Ovarian Cancer Validation Test Specimens
- Cherubim Interests, Inc. (CHIT) Announces End of Year Convertible Preferred Stock Dividend
- Dominovas Energy Corp. (DNRG) Signs Financing Agreement With GHS Capital
- Elephant Talk Communications Corp. (ETAK) Announces the Appointment of Robert H. Turner as Executive Chairman; Names ETNA President Tim Payne as Interim CEO
- Freedom Leaf Inc. (FRLF) Licensing Its Brand for National Growth on the Grass Roots Level
- Giggles N' Hugs, Inc. (GIGL) Signs Agreement with New York-Based Chardan Capital Markets
- GTX Corp. (GTXO) Launches New Track My Workforce Mobile App and Tracking Portal
- Hemp, Inc. (HEMP) Two Days Left to Buy Hemp Jeans by Hemp Blue
- International Stem Cell Corp. (ISCO) Announces Launch Plans for New Nano-Compound Products
- Latitude 360, Inc. (LATX) Multi-Dimensional Entertainment Eatery Enhances Guest Experience and Engagement Through Partnership With MyCheck
- Legacy Ventures International, Inc. (LGYV) Award-Winning Actor, Screenwriter, Director, Producer and Jazz Vocalist, Robert Davi, Joins Legacy Ventures
- Lingo Media Corp. (LMDCF) Continues to Generate Strong Profits with Q3 Net Income of $631,730
- Moxian, Inc. (MOXC) MissionIR Exclusive Audio Interview With Moxian Creative & Marketing VP Edmund Ooi
- Nutra Pharma Corp. (NPHC) StockNewsNow.com Publishes New SNNLive Video Interview With Nutra Pharma Corp.
- Oakridge Global Energy Solutions, Inc. (OGES) Announces Q3 Results
- OurPet's Company (OPCO) Dean Tsengas Named Chief Operations Officer of OurPet's Company
- Star Mountain Resources Inc. (SMRS) Closes Acquisition of Balmat Zinc Mine in New York State
- WRIT Media Group, Inc. (WRIT) Retro Infinity Kickstarter Campaign to Open an Awesome, Innovative Way to Play Classic Video Games